Physician profile
Robert Gioia
NPI 1689022543
$3,088.91
in general payments reported to CMS, 2019-2025
15 companies · $1,602 in 2025
The $1,602 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62.37 · 2024: $1,425 · 2025: $1,602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,027.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,026.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,120.79 | 2024-2025 | Apretude, Dovato |
| Gilead Sciences, INC. | $909.04 | 2024-2025 | Biktarvy, Descovy, Yeztugo |
| Novo Nordisk INC | $350.97 | 2024-2025 | Ozempic, Rybelsus |
| Edwards Lifesciences Corporation | $137.48 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $124.99 | 2025 | Airsupra |
| Intuitive Surgical, INC. | $109.92 | 2024 | |
| Abbott Laboratories | $77.46 | 2024-2025 | Freestyle Libre 3 |
| Dynavax Technologies Corporation | $62.37 | 2019 | |
| Emd Serono, INC. | $56.53 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $32.63 | 2025 | Pifeltro, Delstrigo, Capvaxive |
| Amgen INC. | $31.91 | 2025 | Repatha, Otezla |
| Boston Scientific Corporation | $26.25 | 2024 | Watchman Flx |
| Novartis Pharmaceuticals Corporation | $17.68 | 2025 | |
| Lilly USA, LLC | $15.46 | 2024 | Mounjaro, Zepbound |
| Dexcom, INC. | $15.43 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Gioia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.